A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine design...

Full description

Bibliographic Details
Main Authors: Neeta Somaiah, Sant P. Chawla, Matthew S. Block, John C. Morris, Khanh Do, Joseph W. Kim, Mihaela Druta, Kamalesh K. Sankhala, Patrick Hwu, Robin L. Jones, Sacha Gnjatic, Seunghee Kim-Schulze, Kevin Tuballes, Mahlet Yishak, Hailing Lu, Adam Yakovich, Jan Ter Meulen, Michael Chen, Richard T. Kenney, Chet Bohac, Seth M. Pollack
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
ny-eso-1
vaccine
immunotherapy
lv305
g305
synovial sarcoma
myxoid liposarcoma
prime-boost
lentivirus
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1847846

Similar Items

Similar Items